Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 4, 2020
Daily News
August 4, 2020
- Japan Sketches Out Stable API Supply Measures, Set to Pick Key Drugs from 551 Candidates by March-End
August 4, 2020
- 4 More Products Recalled over Flawed Testing at Kyowa CritiCare
August 4, 2020
- Kyorin Out-Licenses Hearing Loss Med to Otonomy
August 4, 2020
- Paper Maker Oji Ventures into Pharma Biz with Wood-Derived Drugs, Eyes Clinical Trial by 2023
August 4, 2020
- Eisai Shakes Off Price Cut, Coronavirus Blow with Lenvima Growth in Q1
August 4, 2020
- Tetsunari Kihira Appointed as Pharmaceutical Management Director
August 4, 2020
- 2 Astellas Sales Reps Infected with Novel Coronavirus
August 4, 2020
- Daiichi Sankyo to Curb Shipments for Herceptin Biosimilar on Surging Demand
August 4, 2020
- Opdivo-Avastin Combo Hits Goal in Non-Squamous NSCLC; Ono Prepping for Japan Filing
August 4, 2020
- Takeda to Merge Shire Japan in October
August 4, 2020
- JCR to Start Global Study of MPS I Med; Japan Launch Planned in September
August 4, 2020
- JCR to Boost Manufacturing Capacity for Temcell by 30%
August 4, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…